Patient satisfaction with ExtaviPro™ 30G a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world observational EXCHANGE study

摘要

BackgroundPatients with multiple sclerosis (MS) receiving long-term, subcutaneous interferon β-1b (IFN β-1b; Extavia®) often experience injection-site reactions and injection-site pain, which together with other side-effects (such as flu-like symptoms) result in suboptimal treatment compliance/adherence. The EXCHANGE study evaluated patient satisfaction with IFN β-1b treatment, administered using ExtaviPro™ 30G, a new auto-injector, in a real-world setting.